Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect
CA 2457719 C · Owner: Sigma-Tau Research Switzerland S.A. · Inventors: Casu, Benito; Pisano, Claudio; Naggi, Annamaria
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Partially desulphated glycosaminoglycan derivatives are described particularly heparin, and more particularly formula (I) compounds where the U R and R1 groups have the meanings indicated in the description. Said glycosaminoglycan derivatives are endowed with antiangiogenic and heparanaseinhibiting acitivity ans are devoid of anticoagulant activity.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 12, 2001 and granted January 3, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 12, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 12, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.